Literature DB >> 24563457

Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.

Hyun Seok Hwang1, Florentin R Nitu, Yi Yang, Kafa Walweel, Laetitia Pereira, Christopher N Johnson, Michela Faggioni, Walter J Chazin, Derek Laver, Alfred L George, Razvan L Cornea, Donald M Bers, Björn C Knollmann.   

Abstract

RATIONALE: Calmodulin (CaM) mutations are associated with an autosomal dominant syndrome of ventricular arrhythmia and sudden death that can present with divergent clinical features of catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT syndrome (LQTS). CaM binds to and inhibits ryanodine receptor (RyR2) Ca release channels in the heart, but whether arrhythmogenic CaM mutants alter RyR2 function is not known.
OBJECTIVE: To gain mechanistic insight into how human CaM mutations affect RyR2 Ca channels. METHODS AND
RESULTS: We studied recombinant CaM mutants associated with CPVT (N54I and N98S) or LQTS (D96V, D130G, and F142L). As a group, all LQTS-associated CaM mutants (LQTS-CaMs) exhibited reduced Ca affinity, whereas CPVT-associated CaM mutants (CPVT-CaMs) had either normal or modestly lower Ca affinity. In permeabilized ventricular myocytes, CPVT-CaMs at a physiological intracellular concentration (100 nmol/L) promoted significantly higher spontaneous Ca wave and spark activity, a typical cellular phenotype of CPVT. Compared with wild-type CaM, CPVT-CaMs caused greater RyR2 single-channel open probability and showed enhanced binding affinity to RyR2. Even a 1:8 mixture of CPVT-CaM:wild-type-CaM activated Ca waves, demonstrating functional dominance. In contrast, LQTS-CaMs did not promote Ca waves and exhibited either normal regulation of RyR2 single channels (D96V) or lower RyR2-binding affinity (D130G and F142L). None of the CaM mutants altered Ca/CaM binding to CaM-kinase II.
CONCLUSIONS: A small proportion of CPVT-CaM is sufficient to evoke arrhythmogenic Ca disturbances, whereas LQTS-CaMs do not. Our findings explain the clinical presentation and autosomal dominant inheritance of CPVT-CaM mutations and suggest that RyR2 interactions are unlikely to explain arrhythmogenicity of LQTS-CaM mutations.

Entities:  

Keywords:  calcium; catecholaminergic polymorphic ventricular tachycardia; long QT syndrome; ryanodine receptor calcium release channel; sarcoplasmic reticulum

Mesh:

Substances:

Year:  2014        PMID: 24563457      PMCID: PMC3990285          DOI: 10.1161/CIRCRESAHA.114.303391

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  47 in total

1.  Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hyun Seok Hwang; Can Hasdemir; Derek Laver; Divya Mehra; Kutsal Turhan; Michela Faggioni; Huiyong Yin; Björn C Knollmann
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-01-26

2.  Fluorescence resonance energy transfer-based sensor Camui provides new insight into mechanisms of calcium/calmodulin-dependent protein kinase II activation in intact cardiomyocytes.

Authors:  Jeffrey R Erickson; Ruchi Patel; Amanda Ferguson; Julie Bossuyt; Donald M Bers
Journal:  Circ Res       Date:  2011-08-11       Impact factor: 17.367

3.  Calmodulin modulates the termination threshold for cardiac ryanodine receptor-mediated Ca2+ release.

Authors:  Xixi Tian; Yijun Tang; Yingjie Liu; Ruiwu Wang; S R Wayne Chen
Journal:  Biochem J       Date:  2013-11-01       Impact factor: 3.857

4.  FRET detection of calmodulin binding to the cardiac RyR2 calcium release channel.

Authors:  Tao Guo; Bradley R Fruen; Florentin R Nitu; Trinh D Nguyen; Yi Yang; Razvan L Cornea; Donald M Bers
Journal:  Biophys J       Date:  2011-11-01       Impact factor: 4.033

5.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

6.  Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.

Authors:  Qiang Zhou; Jianmin Xiao; Dawei Jiang; Ruiwu Wang; Kannan Vembaiyan; Aixia Wang; Chris D Smith; Cuihong Xie; Wenqian Chen; Jingqun Zhang; Xixi Tian; Peter P Jones; Xiaowei Zhong; Ang Guo; Haiyan Chen; Lin Zhang; Weizhong Zhu; Dongmei Yang; Xiaodong Li; Ju Chen; Anne M Gillis; Henry J Duff; Heping Cheng; Arthur M Feldman; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Nat Med       Date:  2011-07-10       Impact factor: 53.440

7.  Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.

Authors:  Eleonora Savio Galimberti; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2011-07-12       Impact factor: 5.000

8.  Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.

Authors:  Hiroshi Watanabe; Björn C Knollmann
Journal:  J Electrocardiol       Date:  2011-08-27       Impact factor: 1.438

Review 9.  Genetics of sudden cardiac death syndromes.

Authors:  Nagesh Chopra; Björn C Knollmann
Journal:  Curr Opin Cardiol       Date:  2011-05       Impact factor: 2.161

10.  Mechanism of calmodulin inhibition of cardiac sarcoplasmic reticulum Ca2+ release channel (ryanodine receptor).

Authors:  Le Xu; Gerhard Meissner
Journal:  Biophys J       Date:  2004-02       Impact factor: 4.033

View more
  54 in total

Review 1.  Calcium Revisited: New Insights Into the Molecular Basis of Long-QT Syndrome.

Authors:  John R Giudicessi; Michael J Ackerman
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-07

2.  Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry.

Authors:  Lia Crotti; Carla Spazzolini; David J Tester; Alice Ghidoni; Alban-Elouen Baruteau; Britt-Maria Beckmann; Elijah R Behr; Jeffrey S Bennett; Connie R Bezzina; Zahurul A Bhuiyan; Alpay Celiker; Marina Cerrone; Federica Dagradi; Gaetano M De Ferrari; Susan P Etheridge; Meena Fatah; Pablo Garcia-Pavia; Saleh Al-Ghamdi; Robert M Hamilton; Zuhair N Al-Hassnan; Minoru Horie; Juan Jimenez-Jaimez; Ronald J Kanter; Juan P Kaski; Maria-Christina Kotta; Najim Lahrouchi; Naomasa Makita; Gabrielle Norrish; Hans H Odland; Seiko Ohno; John Papagiannis; Gianfranco Parati; Nicole Sekarski; Kristian Tveten; Matteo Vatta; Gregory Webster; Arthur A M Wilde; Julianne Wojciak; Alfred L George; Michael J Ackerman; Peter J Schwartz
Journal:  Eur Heart J       Date:  2019-09-14       Impact factor: 29.983

3.  Calmodulin inhibition of human RyR2 channels requires phosphorylation of RyR2-S2808 or RyR2-S2814.

Authors:  Kafa Walweel; Nieves Gomez-Hurtado; Robyn T Rebbeck; Ye Wint Oo; Nicole A Beard; Peter Molenaar; Cris Dos Remedios; Dirk F van Helden; Razvan L Cornea; Björn C Knollmann; Derek R Laver
Journal:  J Mol Cell Cardiol       Date:  2019-03-27       Impact factor: 5.000

4.  Calmodulin Mutants Linked to Catecholaminergic Polymorphic Ventricular Tachycardia Fail to Inhibit Human RyR2 Channels.

Authors:  Kafa Walweel; Nieves Gomez-Hurtado; Ye Wint Oo; Nicole A Beard; Cris Dos Remedios; Christopher N Johnson; Walter J Chazin; Dirk F van Helden; Björn C Knollmann; Derek R Laver
Journal:  J Am Coll Cardiol       Date:  2017-07-04       Impact factor: 24.094

5.  Arrhythmogenic calmodulin mutations impede activation of small-conductance calcium-activated potassium current.

Authors:  Chih-Chieh Yu; Jum-Suk Ko; Tomohiko Ai; Wen-Chin Tsai; Zhenhui Chen; Michael Rubart; Matteo Vatta; Thomas H Everett; Alfred L George; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2016-05-07       Impact factor: 6.343

6.  The arrhythmogenic N53I variant subtly changes the structure and dynamics in the calmodulin N-terminal domain, altering its interaction with the cardiac ryanodine receptor.

Authors:  Christian Holt; Louise Hamborg; Kelvin Lau; Malene Brohus; Anders Bundgaard Sørensen; Kamilla Taunsig Larsen; Cordula Sommer; Filip Van Petegem; Michael Toft Overgaard; Reinhard Wimmer
Journal:  J Biol Chem       Date:  2020-04-21       Impact factor: 5.157

7.  Essential Role of Calmodulin in RyR Inhibition by Dantrolene.

Authors:  Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver
Journal:  Mol Pharmacol       Date:  2015-04-28       Impact factor: 4.436

Review 8.  Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?

Authors:  Michela Faggioni; Christian van der Werf; Bjorn C Knollmann
Journal:  Trends Cardiovasc Med       Date:  2014-07-10       Impact factor: 6.677

Review 9.  Towards a Unified Theory of Calmodulin Regulation (Calmodulation) of Voltage-Gated Calcium and Sodium Channels.

Authors:  Manu Ben-Johny; Ivy E Dick; Lingjie Sang; Worawan B Limpitikul; Po Wei Kang; Jacqueline Niu; Rahul Banerjee; Wanjun Yang; Jennifer S Babich; John B Issa; Shin Rong Lee; Ho Namkung; Jiangyu Li; Manning Zhang; Philemon S Yang; Hojjat Bazzazi; Paul J Adams; Rosy Joshi-Mukherjee; Daniel N Yue; David T Yue
Journal:  Curr Mol Pharmacol       Date:  2015       Impact factor: 3.339

10.  Calmodulin mutations associated with long QT syndrome prevent inactivation of cardiac L-type Ca(2+) currents and promote proarrhythmic behavior in ventricular myocytes.

Authors:  Worawan B Limpitikul; Ivy E Dick; Rosy Joshi-Mukherjee; Michael T Overgaard; Alfred L George; David T Yue
Journal:  J Mol Cell Cardiol       Date:  2014-05-08       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.